STING-deficient mice showed reduced endothelial inflammation (in adipose tissue), alleviated IR and glucose intolerance [132], suggesting that it appears to be viable to develop STING inhibitors for NASH management. This evidence concerns the gene STING1 and metabolic dysfunction-associated steatohepatitis.